Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP414417.RAvHWo3byR5q8EtkeeW9pYt38BsFtLdb_Cu1fp2svc4uQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP414417.RAvHWo3byR5q8EtkeeW9pYt38BsFtLdb_Cu1fp2svc4uQ130_assertion type Assertion NP414417.RAvHWo3byR5q8EtkeeW9pYt38BsFtLdb_Cu1fp2svc4uQ130_head.
- NP414417.RAvHWo3byR5q8EtkeeW9pYt38BsFtLdb_Cu1fp2svc4uQ130_assertion description "[Using pancreatic cancer microarrays and immunohistochemistry, we determined that 6% (4 of 46 and 5 of 100 in two independent panels) of pancreatic adenocarcinomas overexpress cyclin E. We identified two potential mechanisms for this overexpression including the amplification/gain of CCNE1 gene copies in the Panc-1 and Su86.86 cell lines and a novel somatic homozygous mutation (H460R, in one of 11 pancreatic cancer xenografts having allelic loss) in FBXW7, which was accompanied by cyclin E overexpression by immunohistochemistry.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP414417.RAvHWo3byR5q8EtkeeW9pYt38BsFtLdb_Cu1fp2svc4uQ130_provenance.
- NP414417.RAvHWo3byR5q8EtkeeW9pYt38BsFtLdb_Cu1fp2svc4uQ130_assertion evidence source_evidence_literature NP414417.RAvHWo3byR5q8EtkeeW9pYt38BsFtLdb_Cu1fp2svc4uQ130_provenance.
- NP414417.RAvHWo3byR5q8EtkeeW9pYt38BsFtLdb_Cu1fp2svc4uQ130_assertion SIO_000772 14507635 NP414417.RAvHWo3byR5q8EtkeeW9pYt38BsFtLdb_Cu1fp2svc4uQ130_provenance.
- NP414417.RAvHWo3byR5q8EtkeeW9pYt38BsFtLdb_Cu1fp2svc4uQ130_assertion wasDerivedFrom befree-2016 NP414417.RAvHWo3byR5q8EtkeeW9pYt38BsFtLdb_Cu1fp2svc4uQ130_provenance.
- NP414417.RAvHWo3byR5q8EtkeeW9pYt38BsFtLdb_Cu1fp2svc4uQ130_assertion wasGeneratedBy ECO_0000203 NP414417.RAvHWo3byR5q8EtkeeW9pYt38BsFtLdb_Cu1fp2svc4uQ130_provenance.